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Abstract: Phaeodactylum tricornutum (P. tricornutum) comprise several lipophilic constituents with
proposed anti-obesity and anti-diabetic properties. We investigated the effect of an ethanolic
P. tricornutum extract (PTE) on energy metabolism in obesity-prone mice fed a high fat diet (HFD).
Six- to eight-week-old male C57BL/6J mice were switched to HFD and, at the same time, received
orally placebo or PTE (100 mg or 300 mg/kg body weight/day). Body weight, body composition, and
food intake were monitored. After 26 days, blood and tissue samples were collected for biochemical,
morphological, and gene expression analyses. PTE-supplemented mice accumulated fucoxanthin
metabolites in adipose tissues and attained lower body weight gain, body fat content, weight of
white adipose tissue (WAT) depots, and inguinal WAT adipocyte size than controls, independent of
decreased food intake. PTE supplementation was associated with lower expression of Mest (a marker
of fat tissue expandability) in WAT depots, lower gene expression related to lipid uptake and
turnover in visceral WAT, increased expression of genes key to fatty acid oxidation and thermogenesis
(Cpt1, Ucp1) in subcutaneous WAT, and signs of thermogenic activation including enhanced UCP1
protein in interscapular brown adipose tissue. In conclusion, these data show the potential of PTE to
ameliorate HFD-induced obesity in vivo.
Keywords: Phaeodactylum tricornutum; microalgae; fucoxanthin; eicosapentanoic acid; obesity;
browning; brown adipose tissue
1. Introduction
Microalgae constitute a sustainable source of a multitude of nutrients with interesting properties
such as proteins,ω-3 fatty acids, carotenoids, vitamins, and minerals [1], leading to an increasing market
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of microalgae-containing nutraceuticals and food products with important clinical and economic
implications [2]. The marine diatom microalga Phaeodactylum tricornutum has potential for use in
animal feed and human nutrition especially because it contains polyunsaturated fatty acids (PUFAs)
and phytochemicals (e.g., polyphenols and carotenoids) [3,4]. P. tricornutum is particularly enriched
in theω-3 PUFA eicosapentanoic acid (EPA) [5,6] and the carotenoid fucoxanthin [6,7], which likely
mediate the physiological and nutritional value of this microalga. Beneficial health effects such as
anti-inflammatory [8–12], anti-obesity, and anti-diabetic effects [13–18] have been reported in cell and
in vivo studies for these two compounds, mostly derived from fish oil (EPA) and edible macroalgae
(fucoxanthin). The anti-obesity effects ofω-3 long-chain PUFA comprise decreased lipogenesis and
the enhancement of fatty acid oxidation in liver and adipose tissues [13,19]. Fucoxanthin anti-obesity
activity has been attributed to the stimulation of thermogenesis by increasing the expression of
uncoupling protein 1 (UCP1) in adipose tissues [16,17,20] as well as to effects on intestinal lipid
absorption and lipid metabolism [17,20–23]. UCP1 is a mitochondrial inner membrane protein,
typically expressed in brown adipose tissue (BAT) and inducible in white adipose tissue (WAT)
through a process known as WAT browning or beigeing [24], whose activity allows the dissipation of
substrate-derived energy as heat.
Despite its interesting composition, few studies to date have addressed the anti-obesity properties
of P. tricornutum in vivo [25,26]. In these studies, supplementation of the diet with P. tricornutum
lipid extract [25] or P. tricornutum powder [26] ameliorated body weight and body fat gain of mice
on a high fat diet (HFD) independently of decreases in food intake. In the study of Kang et al.,
supplementation was also shown to ameliorate HFD-induced metabolic derangements, such as
hyperglycemia, hyperlipidemia, and insulin resistance, and to exert antioxidant effects in the liver [25].
In the study by Kim et al., evidence was provided that P. tricornutum powder may activate the
AMP-activated protein kinase (AMPK) pathway in the liver [26]. However, these previous reports did
not address changes in cellular and metabolic features of adipose tissues as potential contributors to
the anti-obesity activity of P. tricornutum supplementation.
We here aimed to investigate the ability of a lipophilic ethanol extract of P. tricornutum (PTE) to
oppose the development of obesity in obesity-prone (C57BL/6J) mice fed an obesogenic HFD, with
focus on effects in adipose tissues. Therefore, body weight gain, adipose depots weight, adipocyte size
distribution, and expression in adipose tissues of selected genes related to lipid and energy metabolism
were analyzed, together with parameters related to glucose control.
2. Materials and Methods
2.1. Materials
Chemicals were purchased from Merck (Darmstadt, Germany), Sigma-Aldrich (Taufkirchen,
Germany), and VWR (Bruchsal, Germany) or from Carl Roth (Karlsruhe, Germany), unless
otherwise noted.
2.2. Microalgae Cultivation, Processing, and Preparation of Ethanolic Extract
The P. tricornutum strain UTEX 640 (SAG 1090-1b) was obtained from the culture collection of Algae
(SAG) from the University of Goettingen (Germany) and was cultivated under controlled and axenic
conditions, as described previously [27]. The biomass was harvested by centrifugation, the supernatant
was discarded, and the remaining pellets were stored at −20 ◦C until cell disruption. The biomass of
several cultivations was combined and lyophilized, and it was protected from light in a Christ Alpha
1–2 LD freeze drier (Osterode a. Harz, Germany). This was followed by cell disruption using the
tissue homogenizer Precellys 24 from Bertin Technologies (Frankfurt/Main, Germany). The resulting
P. tricornutum powder was applied to pressurized liquid extraction (ASE 350, Thermo-Fisher Scientific,
Waltham, MA, USA) in accordance with the method described earlier by Derwenskus et al. using
ethanol as extraction solvent [6]. The obtained extract was aliquoted, the ethanol was evaporated
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under a stream of nitrogen, and the extract was stored at −80 ◦C until used for animal experiments.
In order to apply PTE to the mice, the dried extract was resolved in olive oil:water (2:1, v:v) to achieve
a concentration of 0.1 mg/µL or 0.3 mg/µL and homogenized in an ultrasonic bath for 5 min.
2.3. Animal Experiment
The study was approved by the Bioethical Committee of the University of the Balearic Islands
(UIB, Ref. CEEA 43/07/15). International standards for the use and care of laboratory animals were
followed. C75Bl/6J mice were originally obtained from Charles River Laboratories (Barcelona, Spain)
and expanded at the UIB animal house. The animals were housed in standard cages (without running
wheel) at 22 ◦C with a 12-h light/dark cycle and ad libitum access to food (chow) and water. One week
prior to the start of the experiment, six- to eight-week-old male C75BL/6J mice were divided into three
groups with six animals per group (three animals per cage) and switched from chow to a defined low
fat diet (3.8 kcal/g, 10% energy as fat, Research Diets D12450J, New Brunswick, NJ, USA). The diet was
then changed to a defined HFD containing 4.7 kcal/g and 45% energy as fat (Research Diets D12451).
At the same time as the HFD, the animals received daily, orally with the aid of a pipette, the vehicle
(olive oil:water, 2:1, v:v) (placebo group) or PTE at a dose of 100 mg/kg body weight (bw)/day (PTE100)
or 300 mg/kg bw/day (PTE300). Body weight and food intake were regularly monitored. Food intake
was estimated on a per-cage basis, from the actual amount of food consumed by the animals and its
caloric equivalence. Body composition was analyzed using an Echo MRI body composition analyzer
(EchoMRI, LLC, Houston, TX, USA). At day 22, animals were starved for 6 h (from 06:00 a.m. to
12:00 p.m.) after which tail blood was collected for the measurement of circulating parameters. After
26 days, the animals were euthanized. Blood, liver, and adipose tissues (including interscapular BAT
and epididymal, inguinal, and retroperitoneal WAT) were dissected and stored at −80 ◦C until used for
analysis. Samples of the liver, BAT, and inguinal WAT were fixed for histology.
2.4. Circulating Parameters
Blood glucose was determined using an Accu-Chek Aviva system (Roche Diagnostics, Risch,
Switzerland). Commercial kits for measurement of serum insulin (Mercodia, Uppsala, Sweden),
non-esterified fatty acids (NEFA; Wako Chemicals GmbH, Neuss, Germany) and triacylglycerides
(TAG; Sigma-Aldrich, St. Louis, MO, USA) were applied following the manufacturer’s protocols.
The homeostatic model assessment for insulin resistance (HOMA-IR) and the revised quantitative
insulin sensitivity check index (R-QUICKI) were calculated as described earlier [28].
2.5. Total Liver Fat Content
The total fat content in the liver was determined by Folch extraction with minor modifications [29].
In brief, 50–80 mg of fresh liver was weighted in a sample tube, followed by adding 500 µL of PBS and
homogenization with a sonication probe for 10 s. To each sample, 500 µL methanol were added, mixed
thoroughly for 2 min, followed by addition of 1 mL chloroform and mixing for 2 min. The mixture was
centrifuged for 3 min at 4000× g, and the lower chloroform phase was transferred to a new tube using
a glass pipette. The extraction procedure was repeated three times, and the solvent was evaporated
under a stream of nitrogen. The tube with the dried residue was weighed, and the total fat content was
calculated by subtracting the weight of the empty tube.
2.6. Carotenoid and Fatty Acid Analyses
Fatty acids in PTE were analyzed, as described earlier [6], using gas chromatography and a
flame ionization detector. Carotenoids in PTE and in liver, BAT, and epididymal and inguinal WAT
samples of animals were analyzed by HPLC coupled to a photodiode array detector, as described
previously [6,30].
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2.7. Total RNA Isolation and Quantitative Real Time PCR (qPCR) Analysis
Total RNA was extracted from tissues or cells using TRI Reagent (Sigma-Aldrich, St. Louis,
MO, USA) following the manufacturer’s instructions. Isolated RNA was quantified using NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE, USA) and its integrity
confirmed by agarose gel electrophoresis. A 0.25 µg sample of total RNA was reverse-transcribed using
reagents from Life Technologies (Carlsbad, CA, USA). The resulting cDNA was subjected to qPCR
analysis on a StepOnePlus instrument (Life technologies). Hprt-1 transcript was used as a reference
housekeeping gene. The sequences of the employed primers for qPCR are available on request.
2.8. Histology and Immunohistochemistry
Tissue samples were fixed by immersion in 4% paraformaldehyde in 0.1 M sodium phosphate
buffer, pH 7.4, overnight at 4 ◦C, dehydrated in a graded series of ethanol, cleared in xylene, and
embedded in paraffin blocks for light microscopy. Five-micrometer-thick sections of tissues were cut
with a microtome, mounted on slides, and stained with hematoxylin/eosin. Morphometric analysis of
inguinal WAT sections was performed by digital acquisition of adipose tissue areas using AxioVision
40V 4.6.3.0 software and a Zeiss Axioskop 2 microscope equipped with an AxioCam ICc3 digital camera
(Carl Zeiss S.A., Barcelona, Spain). Distributions of adipocyte size were obtained from individual
data of cell sizes. Immunohistochemical detection of UCP1, mitofusin-2 (MFN2), and galectin-3
in fixed tissue sections was performed, essentially as previously described [31], using polyclonal
antibodies against UCP1 (Catalog number GTX112784, GeneTex, Irvine, CA, USA), Mfn2 (Catalog
number HPA030554, Sigma-Aldrich, St. Louis, MO, USA), and galectin-3 (MAC-2; Catalog number
CL8942AP, Cedarlane, Burlington, Ontario, Canada).
2.9. Immunoblotting
Total protein was isolated from tissues using TRI Reagent (Sigma-Aldrich, St. Louis, MO, USA)
following the manufacturer’s instructions. Protein concentration was determined with PierceTM BCA
Protein Quantification Assay kit (Thermo-Fisher Scientific, Waltham, MA, USA). Ten micrograms of
protein was loaded and separated in a precast 12% gel (Bio-Rad, Hercules, CA, USA) and transferred
onto a 0.2 µm nitrocellulose membrane using a Trans-Blot Turbo semi-dry transfer apparatus (Bio-Rad,
Hercules, CA, USA). Membranes were blocked for 1 h at room temperature with Odyssey Blocking
Buffer (Li-Cor, Lincoln, NE, USA) and incubated overnight at 4 ◦C with gentle shaking with primary
antibodies (1:1000 in Tris Buffered Saline-Tween 20, TBS-T) against UCP1 and MFN2 (same sources
as in 2.8). Membranes were then incubated with the corresponding secondary IRDye antibodies
(1:10000 in TBS-T, 1 h at room temperature), and the signal was detected using an Odyssey near-infrared
scanner (Li-Cor, Lincoln, NE, USA).
2.10. Cell Culture Experiment
3T3-L1 preadipocytes obtained from ATCC (American Type Culture Collection, Manassas, VA,
USA) were grown and differentiated in six-well culture plates, using commercial media from Zen-Bio Inc
(Research Triangle Park, NC, USA) and following the manufacturer standard protocol. Preadipocytes
were routinely cultured in Preadipocyte medium at 37 ◦C and 5% CO2. For differentiation into
adipocytes, the cells were allowed to reach confluence, and two days later (defined as day zero)
the preadipocyte medium was replaced by Differentiation medium. On day three, differentiation
medium was replaced by Adipocyte Maintenance medium. Cells were cultured until day eight,
with medium replacement every two days. Adipogenic differentiation of the cells was regularly
monitored through phase contrast microscopical examination. On day seven, when more than 95% of
the cells showed intracellular lipid accumulation, cells were treated with PTE (100 mg/L), fucoxanthin
(5 µM; Sigma-Aldrich, St. Louis, MO, USA) or vehicle (ethanol; 10 µL) for 24 h prior to harvesting.
In parallel plates intracellular lipid content was quantified by Oil Red O (ORO) staining, as previously
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described [32], evidencing no differences between treatments (results not shown). The treatments
applied had no cytotoxic effects in 3T3-L1 preadipocytes as assessed by the lactate dehydrogenase
release assay (results not shown).
2.11. Statistical Analysis
Data are presented as mean ± standard deviation (SD) or as mean ± standard error of the
mean (SEM). Comparisons between three groups (placebo, PTE100, and PTE300) were assessed
by a non-parametric Kruskal–Wallis test. To compare between two groups, the non-parametric
Mann–Whitney U test was used. In both cases, threshold of significance was set at p < 0.05. IBM SPSS
Statistics for Windows, version 23.0 (IBM Corp., Armonk, NY, USA) was used for the analyses.
3. Results
3.1. Phaeodactylum tricornutum Extract (PTE) Characterization
The extract contained 15 mg dry matter (dm)/mL. Table 1 shows the fatty acid and carotenoid
composition of PTE. Palmitoleic acid, palmitic acid, and EPA represented the main fatty acids. The PTE
contained relatively high amounts of the carotenoid fucoxanthin and lower amounts of zeaxanthin and
β-carotene.
Table 1. Fatty acid and carotenoid spectra of the ethanolic Phaeodactylum tricornutum extract (PTE).
Constituent Concentration (µg/mg dm)
Fatty acids:
Myristic acid 1.82 ± 0.10
Myristoleic acid 0.30 ± 0.02
Palmitic acid 7.73 ± 0.74
Palmitoleic acid 15.24 ± 0.44
cis-Oleic acid 1.52 ± 0.06
trans-Oleic acid 1.02 ± 0.05
α-Linoleic acid 0.71 ± 0.04
γ-Linoleic acid 0.30 ± 0.01
Eicosatrinoic acid 1.25 ± 0.05
Eicosapentanoic acid 7.32 ± 0.40
Carotenoids:
Fucoxanthin 23.54 ± 0.60
Zeaxanthin 0.30 ± 0.05
β-Carotene 0.12 ± 0.04
dm—dry matter. Data are mean ± SD of three independent measurements.
3.2. PTE Supplementation Led to an Accumulation of Fucoxanthin Metabolites in Adipose Tissues
Animals received through PTE supplementation a daily dose of ~2.4 mg fucoxanthin/kg bw
(PTE100) or ~7.1 mg fucoxanthin/kg bw (PTE300). Fucoxanthin is rapidly metabolized to fucoxanthinol
through deacetylation during intestinal digestion, so that little is absorbed intact, and fucoxanthinol
is further dehydrogenated/isomerized to amarouciaxanthin A in the liver and other tissues [33–35].
Traces of fucoxanthin metabolites, potentially the sum of fucoxanthinol and amarouciaxanthin A [30],
were found in the interscapular BAT of PTE300-supplemented mice and in the epididymal and inguinal
WAT depots of PTE100-supplemented mice, whereas supplementation with PTE300 resulted in a
consistent accumulation up to 1.33 ± 0.72 µg fucoxanthinol/g epididymal WAT and 1.48 ± 0.76 µg
fucoxanthinol/g inguinal WAT. Levels of fucoxanthin metabolites in the liver of all experimental groups
and the adipose tissues of the control (HFD-fed, placebo-treated) group were below detection. Lack
of detection of fucoxanthin metabolites in the liver of PTE-supplemented mice might be consistent
with previous findings that fucoxanthin metabolites have a shorter half-life in the liver than in adipose
tissues [36].
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3.3. PTE Supplementation Partly Counteracted High Fat Diet (HFD)-Induced Obesity
In general, PTE supplementation was well accepted by the animals, and there were no apparent
effects on spontaneous physical activity or adverse health effects. The average initial body weight
was 27.7 ± 0.5 g and did not differ significantly among the three experimental groups. HFD feeding
led to a gradual increase of body weight in the three groups, which was already evident after two
days. The PTE-treated mice gained less body weight than controls upon HFD feeding, an effect that
reached statistical significance for PTE300 (Figure 1A). At the end of the experiment (day 26), control,
PTE100, and PTE300 mice had gained 7.0 ± 0.5, 6.0 ± 1.0, and 4.5 ± 0.5 g; final body weights were
35.1 ± 0.6, 33.5 ± 1.4, and 33 ± 0.7 g, respectively. Differences in body weight gain were not because
of the differences in energy intake, which was similar in the three experimental groups throughout
the entire duration of the HFD challenge (Figure 1B). The PTE300 group also revealed less total
body fat mass than controls in body composition analyses performed after 5, 14, and 22 days on
the HFD (Figure 1C). Body weight lost upon a 6 h fast, used as an indicator of energy expenditure,
was maximal in the PTE300 group (Figure 1D). In keeping with these results, at the end of the
study the mass of the epididymal and inguinal WAT depots was significantly lower (by 24% and
17%, respectively) in the PTE300 group compared with the control group (Figure 1E). There were
no differences between groups in retroperitoneal WAT mass and BAT mass (Figure 1E). The weight
of the epididymal depot expressed as percentage of body weight, which is commonly used as an
adiposity index in mice [37], was significantly lower in the PTE300 group compared to the control
group (Figure 1F). Furthermore, mRNA expression levels of mesoderm-specific transcript homolog
protein (Mest), used as a marker of WAT expansion [38,39], were markedly decreased in inguinal WAT
of PTE-supplemented mice (Figure 1G). Histological analysis of the liver was largely normal and did
not reveal obvious hepatosteatosis in any of the experimental groups, possibly because of the relatively
short period of HFD feeding applied (Supplementary Figure S1A). Biochemical analysis showed a
tendency for lower total liver lipid content in the PTE-supplemented mice (Supplementary Figure S1B).
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food (B), and b dy compositi n (C) from day 1 to 26 of ietary challeng . Body w i ht lost upon a 6 h
fast, on day 22 (D). Liver, interscapular b own adi ose tissue (BAT), and inguinal, epididymal, and
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end of the experiment. HFD-fed mice received daily an oral dose of PTE (100 mg or 300 mg/kg bw) or
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between two groups, the non-parametric Mann–Whitney U test was used: *, different (p < 0.05) from
vehicle; and #, different (p < 0.05) between doses.
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Microscopical examination evidenced that inguinal WAT adipocytes were smaller in
PTE-supplemented mice than in control mice (see representative microphotographs in Figure 2A).
Detailed morphometric analysis confirmed a shift of adipocyte population distribution toward
an increased percentage of small adipocytes and a lower percentage of large adipocytes in
PTE-supplemented mice compared to controls (Figure 2B). The Kolmogorov–Smirnov test indicated
that the difference in distributions of cell size between control and PTE-supplemented mice was
statistically significant (p < 0.001 for both PTE doses) (Figure 2B). Microscopical examination of inguinal
WAT sections also revealed a sporadic occurrence of crown-like structures (CLSs) in two out of five
control mice and three out of five PTE100 mice examined, and an even more consistent occurrence of
CLS was found in the PTE300-supplemented group, for which CLSs were detected in all five animals
examined (Supplementary Figure S2). These CLSs were positive for immunostaining against the
macrophage marker galectin-3 (MAC-2).
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adipose tissue (iWAT) of C57BL/6J mice fed with a high fat diet (HFD). Representative microphotographs
illust ating adipocyte size and Mitofusin (MFN) 2 immunostaining (A), and distribution of adipocytes
size (B) in iWAT at the end of the experiment. HFD-fed mice receiv d daily a oral dos of PTE (100 mg
or 300 mg/kg body weight) or placeb (olive oil:water, 2:1, v:v) for 26 d ys. Five to six animals per group
and between 200 and 300 ce ls r animal were included in the analysis of distribution of adipocytes size.
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different (p < 0.001) between the control and the PTE groups, according to the Kolmog rov–Smirnov
test. The bott m panels in (B) correspond to the difference in frequency for each adipocyte ize interval
betw en the PTE-supplemented group (PTE100 or PTE300) and he con rol (vehicle receivi g) group.
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Table 2 shows parameters related to glucose control and insulin sensitivity determined after
a short fasting on day 22 of HFD challenge. There was a tendency for decreased HOMA-IR index
(p = 0.068; Mann–Whitney U test) and increased R-QUICKI index (p = 0.100; Mann–Whitney U
test) in the PTE100-supplemented group, due to lower levels of fasting glucose as well as (though
non-significantly) insulin in blood of animals in this group compared to controls. These results
suggested improved glucose control and insulin sensitivity on HFD in the PTE100 mice. Such trends
were absent in the PTE300-supplemented mice, which had fasting blood glucose levels significantly
higher than control and PTE100-supplemented mice, and fasting insulin, NEFA, HOMA-IR, and
R-QUICKI indexes were very similar to those of control mice. Fed blood glucose levels at the end
of the experiment did not significantly differ between groups (control, 180 ± 8.1; PTE100, 186 ± 9.8;
PTE300, 191 ± 10.7 mg/dL).
Table 2. Plasma analyses and insulin resistance/sensitivity indexes in animals.
Placebo PTE100 PTE300
Glucose (mg/dL) 161 ± 8.2 134 ± 5.8 * 179 ± 5.5 *#
Insulin (mU/L) 42.1 ± 7.8 27.7 ± 1.9 33.5 ± 2.4
NEFA (mEq/L) 0.556 ± 0.046 0.714 ± 0.083 0.661 ± 0.113
HOMA-IR 17.0 ± 3.5 9.1 ± 0.71 14.7 ± 0.94 #
R-QUICKI 0.283 ± 0.005 0.295 ± 0.005 0.281 ± 0.005
Data are mean ± SEM; n = 5–6; Parameters were obtained from blood collected at day 22 after a 6 h fast. To compare
between two groups, the non-parametric Mann–Whitney U test was used: *, different (p < 0.05) from vehicle; and #,
different (p < 0.05) between doses; NEFA—non esterified fatty acids; HOMA-IR—homeostatic model assessment for
insulin resistance; R-QUICKI—revised quantitative insulin sensitivity check index; PTE100—100 mg PTE/kg body
weight/day; and PTE300—300 mg PTE/kg body weight/day.
3.4. PTE Supplementation Affected Transcriptional Control of Lipid Metabolism in White Adipose Tissue
(WAT) Depots and Favored Browning of Subcutaneous WAT
Gene expression of key proteins related to different aspects of fatty acid and energy metabolism
was compared in visceral (epididymal) and subcutaneous (inguinal) WAT depots of control and
PTE-supplemented mice under HFD. In the epididymal WAT of PTE-supplemented mice, mRNA levels
of lipolysis-related genes Lipe, encoding hormone sensitive lipase, and Plin1, encoding perilipin 1, were
significantly down-regulated (p = 0.039 and p = 0.033, respectively; Kruskal–Wallis test), and there
were trends to down-regulation for the lipogenesis-related gene Srebf1 and the fatty acid uptake-related
gene Cd36 as well (p = 0.099 and p = 0.078, respectively; Kruskal–Wallis test) (Figure 3A). Further,
mRNA levels in the epididymal fat depot of Lpl, coding for lipoprotein lipase that enables utilization
of fatty acids from circulating triacylglycerols, were significantly down-regulated in the PTE300 mice
relative to controls.
In subcutaneous (inguinal) WAT, expression of these same genes was unaffected by PTE
supplementation (Figure 3B). However, Cpt1 was 4 times and Ucp1 at least 11 times upregulated in
inguinal WAT of PTE-supplemented mice, indicating an increased capacity for fatty acid oxidation
and thermogenesis (Figure 3B) (p = 0.085 and p = 0.022, respectively; Kruskal–Wallis test). Further,
at the protein level, UCP1 could not be detected in inguinal WAT in any control mice, but it was
detected by immunoblotting in one-sixth PTE100 and two-fifths PTE300 mice analyzed (results not
shown). Moreover, immunostaining of inguinal WAT sections for MFN2—an outer mitochondrial
membrane protein whose activity has been linked to an enhancement of oxygen consumption and
substrate oxidation [40]—was more intense in PTE-supplemented mice than in controls (see the brown
color in the periphery of adipocytes in Figure 2A).
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Figure 3. Phaeodactylum tricornut m ethanolic extract (PTE) down-regulates fatty cid uptake and lipid
turnover capacities in epididymal white adipose tissu (eWAT) and incr ases oxidative/thermog nic
capacity in inguinal WAT (iWAT) of C57BL/6J mice fed with a high fat diet (HFD). mRNA levels of
selected genes as indicated were analyzed in eWAT (A) and iWAT (B) at the end of the experiment.
HFD-fed mice received daily an oral dose of PTE (100 mg or 300mg/kg body weight) or placebo
(olive oil:water, 2:1, v:v) for 26 days. Data are the mean ± SEM of 5–6 male mice/group and are expressed
relative to the mean value of the vehicle group, which was set to 100. To compare between two groups,
the non-parametric Mann–Whitney U test was used: *, different (p < 0.05) from vehicle.
3.5. PTE Supplementation Favored Brown Adipose Tissue (BAT) Activation
PTE supplem ntatio led to BAT activation as i dica ed by the small r size of brown a ipocytes
and th ir enrichment in UCP1 prot in immunostaining (see the repres ntative icro hotographs
in Figure 4 ). This was confirmed by immunoblotting analy is of UCP1 and MFN2, showing
dose-dependent increased l vels of both proteins in BAT of PTE-supplemented animals as compared to
controls (F gure 4B). Moreover, PTE-suppl mented m ce showed an increased gene expression in BAT
of Cd36 (p = 0.046; Kruskal–Wallis t st) that was especially evident in the PTE100 group, which als
showed increased mRNA levels of Ppargc1a in BAT (Figure 4C). PTE supplementation had no effect
on the expression of Ucp1 or Cpt1 at the mRNA level, d result d i a downr gulated expression
in BAT of the lipolytic genes Lipe and Pnpla2 (p = 0.029 and p = 0.057, respectively; Kruskal–Wallis
test), e c ding hormone sensitive lipase and adipose triglyceride lipase. mRNA levels of the lipogenic
genes Fasn and Srebf1 were also down-regulated in BAT of PTE-supplemented mice (p = 0.049 and
p = 0.074, respectively; Kruskal–Wallis test) (Figure 4C).
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PTE/L, contributing ~3.6 µM fucoxanthin, or a similar dose of pure fucoxanthin (5 µM) for 24 h 
(Figure 5). Cpt1a mRNA levels were strongly, relative to levels in control cells, similarly induced by 
both PTE and fucoxanthin exposure. Cd36 mRNA levels were induced following exposure to PTE, 
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Figure 4. Phaeodactylum tricornutum ethanolic extract (PTE) activates interscapular brown adipose tissue
(BAT) in C57BL/6J mice fed with a high fat diet (HFD). Representative microphotographs illustrating
BAT activation and Uncoupling protein (UCP) 1 immunostaining (A), UCP1 and Mitofusin (MFN) 2
protein levels as determined by immunoblotting in BAT (B), and mRNA levels of selected genes in BAT
(C) at the end of the experiment. HFD-fed mice received daily an oral dose of PTE (100 mg or 300 mg/kg
body weight) or placebo (olive oil:water, 2:1, v:v) for 26 days. Data are the mean ± SEM of 5–6 male
mice/group and are expressed relative to the mean value of the vehicle group, which was set to 100.
To compare between two groups the non-parametric Mann–Whitney U test was used: *, different from
vehicle; and #, different between doses. Threshold of statistical significance was set at
mboxemphp < 0.05; in (B), p values < 0.1 are also indicated.
3.6. PTE and Fucoxanthin had Both Overlapping and Distinct Effects on Gene Expression of Lipid
Metabolism-Related Genes in Mature 3T3-L1 Adipocytes
Expression levels of a series of genes related to lipid metabolism and thermogenesis were
compared in mature 3T3-L1 adipocytes exposed to the vehicle (control cells) or to either 100 mg PTE/L,
contributing ~3.6 µM fucoxanthin, or a similar dose of pure fucoxanthin (5 µM) for 24 h (Figure 5).
Cpt1a mRNA levels were strongly, relative to levels in control cells, similarly induced by both PTE
and fucoxanthin exposure. Cd36 mRNA levels were induced following exposure to PTE, but not
fucoxanthin, whereas Fasn mRNA levels were decreased following exposure to fucoxanthin, but not
PTE. Ucp1 mRNA could not be detected in mature 3T3-L1 adipocytes irrespective of treatment.
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Figure 5. Phaeodactylum tricornutum ethanolic extract (PTE) and fucoxanthin effects on gene expression
in mature 3T3-L1 adipocytes are not equivalent. mRNA levels of selected genes in mature 3T3-L1
adipocytes are shown. 3T3-L1 preadipocytes were gro n and differentiated following a standard
protocol. On day 7, cultures were treated with PTE (100 mg/L), fucoxanthin (5 µM; Sigma-Aldrich),
or vehicle (ethanol 0.5%) for 24 h. Data are the mean ± SEM of two independent experiments made
in triplicate and are expressed relative to the mean value of the vehicle group, which was set to 100.
To compare between two groups the non-parametric Mann–Whitney test was used: *, different from
vehicle; and ‡, different from fucoxanthin. Threshold of statistical significance was set at p < 0.05,
p values < 0.1 are also indicated.
4. Discussion
The current obesity pandemic [41] is boosting research on the use of plant and algae-based
products including extracts or isolated components in obesity prevention and therapy [42,43]. Adipose
tissues are active players in energy metabolism and a target of anti-obesity strategies. WAT is the
main storage site of excess energy taken up from food, and both WAT and BAT are plastic tissues
where substrate (mainly fatty acid) oxidation and thermogenesis can be activated, through pharma
or food compounds, to oppose body fat accrual and preserve metabolic health [44–47]. In this work,
we provide evidence that an ethanolic extract of the microalga Phaeodactylum tricornutum ameliorates
the development of diet-induced obesity and insulin resistance in mice independent of decreased
food intake. P. tricornutum supplementation was linked to increased energy expenditure, as indicated
by increased body weight loss upon fasting, molecular and histological signs of BAT activation,
and molecular signs of enhanced mitochondrial oxidative metabolism in subcutaneous WAT. Thus,
the results point to thermogenesis and metabolic activation in adipose tissues as one mechanism for
the anti-obesity effects of PTE, even if (as a limitation of the study) indirect calorimetry measurements
of energy expenditure are lacking. Other mechanisms that could be involved are decreased dietary
lipid absorption, since energy excreted in feces was not measured, and increased spontaneous physical
activity, since this parameter was not continuously monitored.
An effect of lipophilic constituents of P. tricornutum on obesity-related metabolic changes was
suggested by previous findings. In particular, studies have reported anti-obesity effects of isolated
fucoxanthin or fucoxanthin-containing extracts of edible seaweeds (macroalgae) such as Undaria
pinnatifida or Laminaria japonica in genetic and dietary rodent models of obesity, which have been
ascribed to metabolic effects in tissues including, notably, the adipose tissues [16,17,20,23]. P. tricornutum
is 10 times richer in fucoxanthin than macroalgae [7]. Further, in previous studies we found a
dose-dependent accumulation of fucoxanthin metabolites in adipose tissues of mice that were fed
diets containing 5% to 25% P. tricornutum biomass [30,48]. This scenario prompted us to assay the
anti-obesity activity of an ethanolic extract of P. tricornutum (PTE) with focus on its impact on energy
and lipid metabolism in white and brown adipose tissues.
Mice on HFD receiving PTE supplementation accumulated fucoxanthin metabolites in adipose
tissues, as expected [30,48], and displayed lower body weight gain, body fat content, and weight of WAT
depots than control mice receiving placebo. Whereas effects on macroscopic biometric parameters were
observed mainly at the high PTE300 dose, it is noteworthy that favorable effects of supplementation on
adipocyte size and distribution (e.g., decreased mean adipocyte size, increased proportion of small
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adipocytes, and decreased proportion of large adipocytes) were already evident in inguinal WAT at
the low PTE100 dose. Smaller adipocytes in obesity have been linked to a better metabolic profile,
both in humans [49] and rodent models [50]. Decreased Mest mRNA levels found in WAT depots of
PTE-supplemented mice are also in keeping with PTE opposing the development of obesity, since
Mest expression is a known predictive marker of WAT expansion sensitive to dietary anti-obesity
interventions [38,39]. Two previous papers evidencing anti-obesity effects of P. tricornutum employed
high or very high doses as lipid extract (0.7% in diet, corresponding to ~800 mg extract/kg bw per day
or ~255 mg fucoxanthin/kg bw per day) [25] or dry powder (15% and 30% in diet, corresponding to ~14
and 36 g dry powder/kg bw per day or ~72 and 155 mg fucoxanthin/kg bw per day) [26], which were
well over the doses used in the present work (100 and 300 mg extract/kg bw per day or 2.4 and 7.1 mg
fucoxanthin/kg bw per day). Further, these previous studies did not address cellular or molecular
effects of supplementation on adipose tissues.
Both visceral (epididymal) and subcutaneous (inguinal) WAT were reduced in mass in the
PTE–supplemented animals compared to controls on the HFD, and molecular results suggest that
metabolic effects in both depots may contribute to the local depot weight reduction and the whole-body
anti-obesity effect of supplementation. On the one hand, gene expression data are suggestive of
decreased lipid uptake and turnover in the visceral (epididymal) fat depot of PTE-supplemented
mice, where gene expressions related to fatty acid uptake (Lpl and Cd36), fatty acid mobilization
from intracellular lipid stores (Pnpla2, Lipe, and Plin1), and fatty acid and triacylglycerol synthesis
(Srebf1 and Fasn) were simultaneously found to be down-regulated. A decreased lipid turnover in
visceral fat might be of interest in the context of obesity, as it has been suggested that increased lipid
turnover in visceral WAT (and/or decreased turnover in subcutaneous WAT) may result in metabolic
complications of overweight or obesity [51].
On the other hand, results herein point to an effect of PTE supplementation favoring the browning
of subcutaneous (inguinal) WAT. Thus, although we lacked to detect the appearance of adipocytes
with the typical brown adipocyte multilocular distribution of intracellular fat, molecular signs of an
enhanced capacity for oxidative metabolism and thermogenesis were present in the inguinal WAT
of PTE-supplemented mice. These included an increased expression of Ucp1 (and probably UCP1),
which is the hallmark of WAT browning, and also Cpt1a and MFN2. The Cpt1a protein product is
traditionally considered the rate-limiting enzyme for long-chain fatty acid uptake and beta-oxidation
by mitochondria [52]. MFN2 is a protein involved in mitochondria dynamics that favors mitochondria
fusion and whose activity enhances mitochondrial oxidative metabolism in cells [40].
Not only WAT browning but also increased phagocytosis of large adipocytes could contribute to
the decreased inguinal WAT mass and the favorable changes in adipocyte size distribution observed in
PTE-supplemented mice relative to controls on the HFD. This is suggested by the increased occurrence
of CLS in WAT of PTE-supplemented mice, especially at the high PTE300 dose. CLS corresponds to
dead adipocytes that are being cleared by surrounding macrophages [53]. The biological significance
of these structures is not straightforward. Massive macrophage infiltration in WAT (especially visceral
WAT) in obesity has been related to pro-inflammatory cytokine production, chronic inflammation,
and systemic insulin resistance [54], yet there is emerging evidence for beneficial functions of WAT
macrophages during diet-induced obesity, as the clearance of dead adipocytes may promote adipocyte
turnover [55,56]. Further studies are required to discard a pro-inflammatory potential of PTE, yet we
note that the increased presence of CLS in inguinal WAT of PTE-supplemented mice did not associate
with an aggravation of insulin resistance on the HFD. On the contrary, PTE100 supplementation
resulted in lower fasting blood glucose levels—in keeping with reported antihyperglycemic effects of
fucoxanthin [12]—and the insulin resistance index (HOMA-IR) of PTE-supplemented mice was
tendentially lower (PTE100) or indistinguishable (PTE300) from that of control mice. Further,
anti-inflammatory effects have been reported for P. tricornutum extracts in cell studies in human blood
mononuclear cells and murine macrophages [57] and for fucoxanthin metabolites in adipocytes [12,58],
and fucoxanthin supplementation is shown to improve skeletal muscle insulin responsiveness in mice
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with genetic diabesity [59]. However, our results do suggest that lower doses of PTE might exert better
effects than higher doses on glucose control and insulin sensitivity.
Observed effects in BAT most likely contribute to the ability of PTE supplementation to counteract
the development of diet-induced obesity. Activation of BAT in the supplemented mice was very
clear from the tissue microphotographs and the results of both BAT UCP1 immunohistochemical
staining and immunoblotting. Activation of BAT was also consistent with the observed up-regulation
of other genes and proteins known to be required for BAT thermogenesis, namely MFN2, Cd36, and
Ppargc1a. MFN2 expression is shown to play a major role in BAT metabolism by physically coupling
the mitochondria with lipid droplets and maintaining mitochondrial oxidative capacity [60]. Cd36
encodes a transport protein present at both the plasma and the mitochondrial membrane that mediates
fatty acid uptake in the cell and the mitochondria, and it is known to play an essential role in BAT
thermogenesis [61,62]. Ppargc1a encodes PGC1α, a transcriptional coactivator first identified for its
stimulatory role of BAT thermogenesis [63]. To be highlighted is the fact that PTE supplementation
exerted opposite effects in visceral WAT and BAT regarding gene expression of proteins for cellular
fatty acid provision and uptake (Lpl and Cd36), decreasing it in the epididymal depot and increasing it
in BAT, while having no effects on these genes in the subcutaneous WAT depot. Overall, these results
suggest that PTE supplementation in the context of HFD may favor channeling of dietary fatty acids
away from visceral fat depots and toward ignition in thermogenic fat tissues, mainly BAT and also
subcutaneous WAT.
In previous animal studies, supplementation with fucoxanthin or fucoxanthin-rich seaweed
extracts led to inconsistent results regarding UCP1 expression in adipose tissues. Different authors
observed either up-regulation [20] or lack of effect on UCP1 expression in BAT [16,64], yet in the
latter reports BAT mass normalized to body weight increased following supplementation (contrary to
WAT mass, which was decreased). Therefore, a contribution of increased BAT activity to observed
anti-obesity effects cannot be discarded. An induction of UCP1 expression in visceral (gonadal) WAT
following fucoxanthin supplementation has been reported and highlighted [16,17,20]; however, other
reports failed to detect UCP1 induction in WAT of supplemented animals [64,65]. Further, visceral
WAT has a minor tendency to turn to a BAT-like phenotype than subcutaneous (inguinal) WAT [66],
yet most previous reports did not compare UCP1 induction in visceral and subcutaneous fat depots.
As an exception, Wu et al. assessed gene expression related to mitochondriogenesis and thermogenesis
in inguinal WAT, gonadal (epididymal) WAT, and BAT of mice fed obesogenic diets supplemented
or not with fucoxanthin [64]. They confirmed an increase in the animals’ metabolic rate following
fucoxanthin supplementation, and—different from our results in PTE-supplemented mice—they found
little evidence of up-regulation of thermogenic genes in BAT and a similar up-regulation of many
of such genes in visceral and subcutaneous WAT (though results for Ucp1 did not reach statistical
significance) [64].
Overall, while most animal studies to date point to anti-obesity properties of fucoxanthin, it would
appear that parameters such as the time length of supplementation and the formulation of the
fucoxanthin source (isolated vs. extract) influence the exact regulatory and metabolic mechanisms
involved. In fact, effects of PTE and purified fucoxanthin on gene expression in mature 3T3-L1
adipocytes were not fully equivalent, suggesting that components other than fucoxanthin contribute
to PTE effects in cultured adipocytes and likely also in supplemented animals in vivo. For different
components of PTE including fucoxanthin, metabolic effects have been related to the induction of
the PGC1α network in adipose tissues [64,67] and the activation of AMPK in tissues such as liver
and muscle [68]. These two molecules are important players in the control of energy metabolism.
While further mechanistic studies are warranted, we note that BAT activation brought about by
PTE supplementation involved the induction of the PGC1α gene (Figure 4), but it did not affect
levels of phosphorylated (active) AMPK nor the ratio phosphoAMPK/totalAMPK in the tissue
(results not shown).
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5. Conclusions
In summary, this work demonstrates that a Phaeodactylum tricornutum extract ameliorates the
development of diet-induced obesity in a well-established rodent model, and it links this effect to the
stimulation of oxidative metabolism in BAT and WAT depots, notably the induction of BAT recruitment
and the browning of subcutaneous WAT. Knowledge on the anti-obesity action of P. tricornutum
and its mechanisms may pave the way for novel uses of this microalga in the functional food and
nutraceutical arena.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/4/796/s1,
Figure S1: Effects of PTE supplementation to C57BL/6J mice fed with a high fat diet on liver histological appearance
and lipid content, Figure S2: Effects of PTE supplementation to C57BL/6J mice fed with a high fat diet on the
appearance of crown-like structures in inguinal white adipose tissue.
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